Market News

Here’s Why Health Catalyst Stock (NASDAQ: HCAT) Surged Almost 30% Today

Shares of Health Catalyst (NASDAQ: HCAT) surged almost 30% in today’s session after it reported earnings for its third quarter of Fiscal Year 2022. Adjusted earnings per share came in at -$0.13, which beat analysts’ consensus estimate of -$0.19 per share.

Sales increased 10.72% year-over-year, with revenue hitting $68.35 million. This beat analysts’ target by $1.56 million.

Looking forward, management is expecting revenue for Q4 2022 to be in the range of $66.9 million to $68.9 million. For reference, analysts were expecting $66.79 million.

Is HCAT Stock a Good Buy?

HCAT stock has a Moderate Buy consensus rating based on four Buys, six Holds, and zero Sells assigned in the past three months. The average HCAT stock price target of $8.34 implies 75.9% upside potential.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More